Unraveling Multiple MHC Gene Associations with Systemic Lupus Erythematosus: Model Choice Indicates a Role for HLA Alleles and Non-HLA Genes in Europeans  by Morris, David L. et al.
ARTICLE
Unraveling Multiple MHC Gene Associations with
Systemic Lupus Erythematosus: Model Choice Indicates
a Role for HLA Alleles and Non-HLA Genes in Europeans
David L. Morris,1 Kimberly E. Taylor,2 Michelle M.A. Fernando,1 Joanne Nititham,2
Marta E. Alarco´n-Riquelme,3,4 Lisa F. Barcellos,5 Timothy W. Behrens,6 Chris Cotsapas,7
Patrick M. Gaffney,4 Robert R. Graham,6 Bernardo A. Pons-Estel,8 Peter K. Gregersen,9 John B. Harley,10
Stephen L. Hauser,11 Geoffrey Hom,6 International MHC and Autoimmunity Genetics Network,16
Carl D. Langefeld,12 Janelle A. Noble,13 John D. Rioux,14 Michael F. Seldin,15 Systemic Lupus
Erythematosus Genetics Consortium,16 Lindsey A. Criswell,2,* and Timothy J. Vyse1,*
We have performed a meta-analysis of the major-histocompatibility-complex (MHC) region in systemic lupus erythematosus (SLE) to
determine the association with both SNPs and classical human-leukocyte-antigen (HLA) alleles. More specifically, we combined results
from six studies and well-known out-of-study control data sets, providing us with 3,701 independent SLE cases and 12,110 independent
controls of European ancestry. This study used genotypes for 7,199 SNPs within the MHC region and for classical HLA alleles (typed and
imputed). Our results from conditional analysis and model choice with the use of the Bayesian information criterion show that the best
model for SLE association includes both classical loci (HLA-DRB1*03:01, HLA-DRB1*08:01, and HLA-DQA1*01:02) and two SNPs,
rs8192591 (in class III and upstream of NOTCH4) and rs2246618 (MICB in class I). Our approach was to perform a stepwise search
from multiple baseline models deduced from a priori evidence on HLA-DRB1 lupus-associated alleles, a stepwise regression on SNPs
alone, and a stepwise regression on HLA alleles. With this approach, we were able to identify a model that was an overwhelmingly better
fit to the data than one identified by simple stepwise regression either on SNPs alone (Bayes factor [BF] > 50) or on classical HLA alleles
alone (BF > 1,000).Introduction
Systemic lupus erythematosus (SLE [MIM 152700]) is one
of the many complex diseases that are still without an
adequate explanation for the known heritability (>66%
in the case of SLE1). Delineating the genetic contribution
to the risk of developing a complex disease, such as SLE,
is complicated by the likelihood that disease is caused by
multiple genes. In this paper, we concentrate on one
region, the extended major histocompatibility complex
(MHC) (Chr6: 26–34 Mb), which is known to be the
most polymorphic region in the genome. The MHC can
be divided into three regions, termed classes I, II, and III.
Classical class I and II loci encode the human leukocyte
antigen (HLA) proteins involved in antigen presentation
to T cells. The class III region contains the greatest density
of genes in the human genome and includes many with
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region is the densest area of the genome for disease associ-
ations,2 and the MHC confers the greatest genetic risk for
SLE in all populations studied by genome-wide association
studies thus far3,4
Understanding the genetic risk of this region is therefore
critical for defining the genetic predisposition to SLE.
However, this region is complex because there is linkage
disequilibrium (LD) spanning the entire extended MHC,
which makes determining the true causal loci very diffi-
cult. There is strong evidence for association at the class
II locus HLA-DRB1 (MIM 142857), in which alleles HLA-
DRB1*03:01 and HLA-DRB1*15:01 are consistently repli-
cated.5–7 There have also been associations with other
alleles such as HLA-DRB1*08:018 and HLA-DRB1*14:01.7
However, because of strong LD in the class II region
(HLA-DR and HLA-DQ), HLA-DRB1 alleles are correlated
with alleles of the class II loci HLA-DQA1 (MIM 146880)and Inflammatory Disease, King’s College London, London SE1 9RT, UK;
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Figure 1. A Flowchart of the Work Flow
for This Study
The asterisk (*) represents information
carried from the HLA-DRB1 analysis to
the SNP analysis conditional on HLA-
DRB1 alleles. The following abbreviation
is used: LR, logistic regression.andHLA-DQB1 (MIM 604305). Therefore, alleles outside of
HLA-DRB1 have often shown evidence of association with
SLE, but this might be due to the LD arising from extended
haplotypes. In northern Europeans, there are two main
extended SLE-associated MHC haplotypes that contain
the class II alleles HLA-DRB1*03:01 and HLA-DRB1*
15:01;5 these extended haplotypes comprise the following
HLA alleles: HLA-A*03:01 – HLA-B*07:02 – HLA-C*07:02 –
HLA-DRB1*15:01 – HLA-DQA1*01:02 – HLA-DQB1*06:02
and HLA-A*01:01 – HLA-B*08:01 – HLA-C*07:01 – HLA-
DRB1*03:01 – HLA-DQA1*05:01 – HLA-DQB1*02:01. Asso-
ciated signals independent of HLA-DRB1 have been
detected, but there is no consensus on where these associ-
ations lie or how many there are. In fact, it is still not clear
whether the genetic risk for SLE lies in HLA alleles alone or
whether other genes outside of classical HLA loci are
affecting disease risk.
Several studies have analyzed genetic variation within
the MHC region with the aim of identifying multiple loci
independently associated with SLE.5–7 Strictly speaking,
this is statistical independence; locus A disease associations
that cannot be explained by the correlation between locus
A and locus B. This does not necessarily mean that the two
associated loci are biologically independent (given that
they might both act on the same pathway). However,
because of the complexity of the region, extended regions
of LD, and a lack of statistical power, the disease-causing
alleles within the MHC have not yet been identified. A
larger study of the MHC in SLE is needed for refining previ-
ously identified signals and for searching for additional
disease-associated loci, and this will require methods
designed to better account for extensive LD in associated
regions. This paper reports on the largest study to date of
SLE association at the MHC in the search for statistically
independent associated loci.
It is common for association studies of the MHC to look
for independent signals by conditioning on the strongestThe American Journal of Human Gensignal by using either HLA alleles or
a SNP as a covariate in logistic re-
gression. What follows is a stepwise
regression where each successive
associated marker is used as an addi-
tional covariate. This approach relies
heavily on the first locus taken as
a covariate and can lead to a subop-
timal final model of association if
the first signal tags two or more asso-
ciations.9 We propose to start the
stepwise search from multiple start-ing points determined from both a priori evidence about
association and analyses of subsets of the data: SNPs
only, HLA alleles only, and separate HLA classes. Our study
therefore takes a broader approach than simply condi-
tioning on the most significant associated signal in the
search for the best model of association within the MHC.
A flowchart of the approach we took can be seen in
Figure 1.
For this study, we obtained data from six sources
(Table 1), as well as additional well-defined control data
(from the Wellcome Trust Case Control Consortium 2
[WTCCC2]12 and the National Institute of Mental Health
[NIMH] [see Web Resources]) and performed a meta-anal-
ysis within the MHC region (Chr6: 26–34 Mb, NCBI build
126) by using an imputation strategy to maximize the
number of markers across all studies. This large study
provided us with a total of 3,701 independent cases and
12,110 control individuals of European ancestry and
genotypes for 7,199 SNPs in the MHC region after imputa-
tion. We had complete HLA-DRB1 typing for one of the
studies; for the other studies, we used imputation of
HLA-DRB1 alleles from SNP genotypes (see Material and
Methods). Imputation was also performed on HLA-B
(MIM 142830), HLA-C (MIM 142840), HLA-DQA1, and
HLA-DQB1. We also had limited typing for HLA-DRB1,
HLA-B, HLA-DQA1, and HLA-DQB1 in one of the studies.
With the complete HLA-DRB1 typing, we were able
to use these data to evaluate the quality of imputation.
Although we were not able to evaluate the accuracy of
HLA-C imputation, the results from the original study13
by the authors of the imputation program we used show
that this locus has an accuracy superior to that of HLA-B
in Europeans (this latter locus performed well in our
study).
These data gave us the opportunity to determine
whether the association signals within the MHC are
primarily due to classical HLA alleles, to only SNPs, or toetics 91, 778–793, November 2, 2012 779
Table 1. Summary of Individual Studies
Study Genome-wide Markers MHC SNPsa Cases Controls External Controls Population Summary
Illumina 550K3 Illumina 317K 2,380 1,137 6,529 3,493 from WTCCC2 European: mixture of UK,
Italian, Spanish, and
North American
Illumina 317K4 Illumina 317K 1,522 413 1,927 1,300 from WTCCC2 European: mixture of UK
and North American
Affy500K10 selected 14Kb 1,468 210 1,707 1,707 from NIMH European: mixture of UK
and North American
Illumina MHC Panel7 384 continental AIMsc 2,360 917 553d N/A European: mixture of UK
and North American
Illumina Custom6 genomic control SNPse 1,230 686 773 N/A European: mixture of UK
and North American
Affy100K11 selected 7Kb 227 338 621 N/A European: mixture of
Swedish and Argentinian
The genome-wide inflation factor for each study (see Material and Methods) is as follows: 1.140 for Illumina 550K, 1.092 for Illumina 317K, 1.000 for Affy500K,
1.000 for Illumina Custom, and 1.094 for Affy100K. For the Illumina MHC Panel study, we found no significant difference between the matched and unmatched
cases for the variable used as the estimation of percent northern European ancestry (rank sum test, p ¼ 0.22). The following abbreviations are used: MHC, major
histocompatibility complex;WTCCC2, Welcome Trust Case Control Consortium 2; NIMH, National Institute of Mental Health; AIMs, ancestry informativemarkers;
and N/A, not available.
aChr6: 26,000–34,000 kb.
bSelected from Affy-Illumina overlap, excluding regions of high LD and SNPs in LD with each other (all R2 < 0.25).
cSee original paper7 for description of selected markers (AIMs).
dThe IlluminaMHC Panel study contained individuals from a previous trio study,7 in which controls genotypes were taken from nontransmitted alleles. See Table S1
for a breakdown of the origin of recruitment.
eGenomic control SNPs included in the Illumina Custom panel.a combination of HLA alleles and other effects indepen-
dent of these alleles.Material and Methods
Ethical Approval
This study was approved by the London Research Ethics
Committee, United Kingdom (ref: 06/MRE02/9). All meta-studies
were previously published.
Study Cohorts and Genotyping
Our analysis incorporated data from six studies. Table S1, available
online, displays the original sample sizes for each study and the
sample sizes for this meta-analysis after reassignment of overlap-
ping individuals. Any subjects who were observed in more than
one study were assigned to a single group on the basis of a variety
of considerations, including density of genotype data and case-
control balance. Table 1 includes details of the genotyping
platforms used for each study and information on genome-wide
markers available for ancestry and relatedness analyses. The
Illumina MHC Panel study contained individuals from a previous
trio-family study,7 in which controls genotypes were taken from
nontransmitted alleles. For all other studies, cases and controls
were independent. We also used genotype data from the
WTCCC212 and the NIMH.
Four-digit HLA-DRB1 data were available for 2,075 individuals:
605 cases from the UK arm of the Illumina Custom study6
and 1,470 individuals (917 cases and 553 nontransmitted-
allele controls) from the Illumina MHC Panel study.7 Details
on the HLA-DRB1 typing can be found in the original study
publications.6,7
Four-digit HLA-B, HLA-DQA1, and HLA-DQB1 data were avail-
able for 326, 340, and 341 cases, respectively, from the UK arm780 The American Journal of Human Genetics 91, 778–793, Novembof the Illumina Custom study (four-digit typing for these genes
was performed at the Anthony Nolan Trust, London, UK with
Luminex One Lambda SSO methodology).
Quality Control
A set of common quality-control filters was applied to each parent
study before they were merged for analysis. Subjects and SNPs
with <90% genotyping were removed, and a lower bound for
minor allele frequency (MAF) was set to 1%. The 90% rate was
selected from a plot of percentage data removed against missing
rate; moving to 95% across studies would have increased the
amount of data removed from <3% to 9%. Differential missing-
ness (between cases and controls) was checked in each study
separately with a threshold set at 105; for SNPs reported in this
paper, over all studies, the range of p values for this test was
0.02–1.00. SNPs were removed by study source for Hardy-
Weinberg disequilibrium with the use of the false-discovery-rate
(FDR)14 procedure with a rate of 0.05. We removed 55 subjects
(one from Illumina 500K, two from Illumina 317K, 14 from Affy-
metrix 100K, and 38 from the Illumina MHC Panel) from all
studies as a result of low genotyping (<90%). Over all studies,
185 SNPs were rejected because of departure fromHardy-Weinberg
equilibrium (HWE) according to the FDR (% 0.05) procedure.
Similarly, 186 SNPs were rejected after quantile-quantile plots
were looked at, and 138 were rejected after a study-wide rejection
level of p < 0.0001 was set.
In order to identify unknown duplicates and first-degree
relatives where feasible, we performed identity-by-descent (IBD)
analysis by using PLINK15 on subsets of cases and controls with
potential overlap. For this we used the same 300K, 14K, and 7K
genome-wide marker sets as described below for the principal-
component analysis (PCA). In order to confirm that the 14K and
7K marker sets were sufficient for this purpose, we performed
IBD analysis by using the 300K, 14K, and 7K marker sets oner 2, 2012
a common set of subjects with known duplicates and first-degree
relatives. Pi_hat, measuring the degree of IBD sharing, was similar
for all three marker sets, and a cutoff of 0.3 was appropriate
throughout for the detection of first-degree relatives. One subject
(the one with the least amount of missing data) from each related
pair (pi_hat > 0.3) or set was retained; for duplicate individuals,
genotypes were merged by consensus call in PLINK.
We removed 203 subjects because of relatedness (IBD > 0.3):
these were five subjects from the NIMH, 59 from the WTCCC2
(four were removed because of relatedness between the 1958 birth
cohort [1958BC] and the National Blood Service [NBS], seven were
removed from within the 1958BC only, and 48 were removed
from the NBS only), and 139 first-degree relatives dropped on
the basis of IBD or relatedness in other studies (89 from Illumina
317K, 39 from the Illumina MHC Panel, and 11 from Illumina
Custom).
Population Substructure
We analyzed population substructure by using PCA in
EIGENSTRAT16 to identify outliers by ancestry and to adjust for
intra-European ancestry in the association analyses. Because the
whole-genome data available were different for each study, we
performed the following series of analyses.
First, for outlier identification (i.e., likely non-European
ancestry), a series of PCAs using EIGENSTRAT16 was performed
with each type of available whole-genome data (300K, 14K,
and 7K). Outliers were removed with sigma > 6 for any of the first
five principal components (PCs) in any of these analyses. For the
Illumina MHC Panel subjects, for whom we only had 384
intercontinental ancestry informative marker data, a previous
STRUCTURE analysis7 was used for identifying and removing
subjects with <90% European ancestry.
We removed 58 individuals (12 from Illumina 500K, 21 from
Illumina 317K, 10 from NIMH, and 15 from WTCCC2) from all
studies after PCA to identify outliers. Table S2 shows the marker
sets, subjects included, and number of outliers identified from
each PCA from each data set. A subset of subjects with known
common four-grandparent origins within the Illumina 550K
data set enabled us to interpret these initial PCAs. Figure S1 shows
a representative set of these PCAs.
For association analysis, we re-ran PCA by using only subjects
allocated to each of the final six groups (after allocation of overlap-
ping subjects and external controls), except for the Illumina MHC
Panel, for which we used a previous estimation of percent
northern European ancestry (with STRUCTURE17). Consistently,
the first PC represented by far the most variance—from observa-
tion of scree plots—and corresponded to a northwest-southeast
European gradient.
The first PC from each PCA (or percent northern European
ancestry for the Illumina MHC Panel) was included as a covariate
in the logistic regressions for adjusting for intra-European
ancestry. The PCwas included in all analyses of SNP and HLA data.
We calculated an inflation factor for each of the four genome-
wide studies by running a case-control analysis with the PCA.
This resulted in the following inflation factors: 1.175 for Illumina
550K, 1.166 for Illumina 317K, 1.000 for Affy500K, and 1.082 for
Affy100K. When the first PC was added in, the inflation factors
were as follows: 1.140 for Illumina 550K, 1.092 for Illumina
317K, 1.000 for Affy500K, and 1.094 for Affy100K. For the Illu-
mina Custom study, an analysis of a subset (458 cases and 382
controls, who were typed on the Illumina omni1-quad as part of
another study18) of the data used in this paper gave an inflationThe Americanfactor of 1.000; the inflation factor for all individuals with the
use of only the genomic control SNPs (54 SNPs) on the custom
chip was 1.209. The Illumina MHC Panel study was well matched
because all the controls were made up of nontransmitted alleles
from 553 of the cases; the remaining 364 cases were not found
to be significantly different from the matched cases for the vari-
able used as estimation of percent northern European ancestry
(rank sum test, p ¼ 0.22).
SNP Imputation
The genotypes for this meta-analysis were obtained from six
different platforms, and, with the exception of the Illumina
317K and 550K platforms, the percentage of overlap was not
high. For example, there are only 737 SNPs common to the Illu-
mina 550K (2,380 MHC SNPs) and the Illumina MHC Panel
(2,360), and there are only 161 SNPs common to the Illumina
317K (1,522) and Affy500K (1,118) MHC regions. Therefore, in
order to combine association results for asmany studies as possible
for each SNP, we used an imputation strategy by using IMPUTE;19
each study was imputed up to the density of the WTCCC2
controls (typed on the Illumina 1.2M chip and Affy v.6.0 chip),
which were used as a reference set (4,793 individuals with 7,119
markers in the MHC). These controls were also used as control
genotypes in the Illumina 550K study (n ¼ 3,493) and the Illu-
mina 317K study (n ¼ 1,300). Howie et al.19 have shown that
using genotypes both as a reference data set and subsequently as
controls in an association analysis does not lead to inflated levels
of false discovery.
We did not make use of additional imputation reference data
(1000 Genomes, HapMap) because the fact that the WTCCC2
control data were of a much higher density than any of the indi-
vidual studies could lead to an imbalance in imputation accuracy
between cases and controls; some difficult-to-impute SNPs would
be more accurately imputed in the WTCCC2 control data than in
the cases, and so this could lead to differences in frequencies.
Because the WTCCC2 data are of higher density, some SNPs (in
1000 Genomes) might have little information in the study data
(low density around the SNP position) but have good information
in the WTCCC2 data. The study data would then have imputed
SNPs with frequencies tending toward the reference data (1000
Genomes), whereas the WTCCC2 data would have well-imputed
SNPs with frequencies more representative of the true genotypes.
The density of SNPs in cases and controls (per study) prior to
imputation was forced to be equivalent (i.e., a SNP that was
present in the cases, but not in controls, or vice versa, was
removed). This guarded against the possibility of spurious associa-
tion arising as a result of an imbalance of imputation accuracy
between cases and controls. This also gave us an extra test of
our imputation because we were able to evaluate the accuracy at
these known but removed genotypes. The results from this
comparison, displayed in Table S3B, also performed well (average
accuracy > 0.94) and were consistent with the quality measures
output by IMPUTE19 in Table S3A.
Measures of imputation performance in each study can be seen
in Tables S3, S5, and S6. For all imputed SNPs (Table S3A), the
average certainty across studies was high (>0.88), and this is
supported by the consistently high scores in the cross-validation
analyses (concordance and R2 > 0.87). The average information
was also high (>0.82), except for the Affy100K (0.64), which
had relatively sparse genotyping overall, and the Illumina MHC
Panel (0.76), which had no genotype data within much of the
extended class I region.Journal of Human Genetics 91, 778–793, November 2, 2012 781
The imputation evaluation specific to our most associated SNPs
(conditional and unconditional on HLA alleles) showed a high
degree of accuracy (>0.9) and certainty (>0.9 for all except on
the Affy100K [>0.7]). The information statistics were lower
for the Affy100K study (0.4 < info < 0.8) than for the others
(all > 0.7) as a result of the lower density of genotyping in this
study, but removing this study from the analysis did not alter
the results. The HWE figures in controls were satisfactory (there
were no significant p values after adjustment for testing eight
SNPs in six studies).
HLA Imputation
We imputed HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, and HLA-
DQB1 by using HLA*IMP13,20 in all the studies. We made use of
the desktop application that comes with this program for quality
control, alignment, and phasing. The imputation was then per-
formed online with the browser application. We took the full set
of post-SNP-imputation SNPs (n ¼ 7,122) as potential predictive
variables, but we removed genotypes if the maximum imputation
probability was less than 0.95 and then removed potential SNPs if
they had more than 10% missingness. The final set of SNPs used
for HLA imputation (usually ~40) is chosen by HLA*IMP inter-
nally. The SNPs used for HLA imputation at each locus are dis-
played in Tables S7A–S7E. Some of these SNPs were typed, and
some were imputed, so we checked the SNP-imputation scores
(‘‘INFO’’ from IMPUTE) for these SNPs; these are displayed in
Tables S7A–S7E for each study. The range of INFO scores was
very high for Illumina 500K, Illumina 317K, Affy500K, the MHC
Panel, and Illumina Custom (it was 0.704–1.000 over all HLA
genes), whereas for the Affy100K study, the range was generally
a little lower (0.654–1.000 over all HLA genes). Although the lower
point of the ranges was around 0.7 for many loci, the majority of
SNPs actually had imputation scores > 0.9.
We had four-digit typing for HLA-DRB1 for the Illumina MHC
Panel study for 917 cases and 553 nontransmitted-allele controls,
and we had four-digit typing for HLA-DRB1 for the Illumina
Custom study for 605 cases. We also had four-digit HLA-B, HLA-
DQA1, and HLA-DQB1 data available for 326, 340, and 341 cases,
respectively, from the Illumina Custom study. We used these data
for cross-validation; the imputed HLA data were compared to the
typed data, and calculations were made for sensitivity, specificity,
correlation squared (R2), frequencies, and accuracy (the number of
correct assignments divided by the total [2 3 n] alleles). Tables
S10A–S10E contain data on this cross-validation for all HLA alleles.
This was assessed on the most likely alleles (reported by HLA*IMP)
for each gene, and because the performance of this was very high,
we used the most likely calls (as opposed to probabilistic data) in
further statistical analysis for association. We also compared our
imputation performance to that of a study of theMHC in rheuma-
toid arthritis (hereafter called the RA study).21 Our accuracy was
very similar to that of the RA study, and the comparison can be
seen in Table S8. We also note that the accuracy reported in the
paper by the authors of HLA*IMP20 agrees with our observed rates
of >90%; our accuracy was higher, and this was predicted by the
authors of HLA*IMP given that they only used two-thirds of the
reference data (because one-third was used for prediction). We
also found, as did they, thatHLA-DRB1 had slightly lower accuracy
than did the other loci.
We were not able to evaluate the performance of HLA-C imputa-
tion. However, this locus was found to be more reliably imputed
than was HLA-B in Europeans in the original study by the authors
of HLA*IMP.13 HLA*IMP has a much larger reference data set than782 The American Journal of Human Genetics 91, 778–793, Novembin the original paper, and so the imputation is most likely more
accurate. From the accuracy reported in the HLA*IMP13 paper,
there is no reason to believe that the performance of HLA-C
imputation is any worse than that of HLA-B, that is, HLA-C is
probably more accurately imputed.
RNA-Expression Data
RNA-expression data were downloaded from the Gene Expres-
sion Omnibus repository (see Web Resources). These data arise
from a study22 of 210 unrelated HapMap individuals, from
whom RNA was extracted from lymphoblastoid cell lines. Geno-
type data for the 210 HapMap individuals were downloaded
from the HapMap website.
Linear regression was performed in R on the RNA-expression
data. Genotype was taken as the explanatory variable coded as
minor allele dosage [0,1,2], and expression levels (log scale,
base ¼ 2) were the outcome. Each of the three SNPs (rs2246618,
rs8192591, and rs2524117) that were associated with SLE inde-
pendently of classical HLA alleles was tested for correlation with
the expression levels of genes closest to the respective SNPs;
rs8192591 was tested against expression for NOTCH4 (MIM
164951), the class I SNPs (rs2246618 and rs2524117) were both
tested against HLA-B and HLA-C expression, and rs2246618 was
also tested against MICB (MIM 602436) expression. Therefore,
we adjusted for six tests in total.
Statistical Analysis: Overview
The SNP and HLA analysis was a multistep process from imputa-
tion to association and model selection. We therefore include
a flow chart (Figure 1) to aid the reader, and we refer to this in
each part of the results section.
Statistical Analysis: SNP Data Only
As a result of differences in the data available for ancestry adjust-
ment, we were not able to simply pool the imputed studies’ data
and analyze as a single group. Thus, we reanalyzed each study
separately and then combined our results via standard meta-
analysis methods (inverse variance method and test for heteroge-
neity of odds ratios [ORs]23).
Association testing was performed for each study with logistic
regression (additive model), accounting for imputation uncer-
tainty via the software SNPTEST.24 We accounted for ancestry by
including the first PC, obtained from PCA using EIGENSTRAT
with available genome-wide markers (see Supplemental Data)
as a covariate. For the Illumina MHC Panel study, we used the
percentage of European ancestry estimated in a previous study.7
After identifying the first top associated SNP (i.e., the SNP with
the lowest p value from the combinedmeta-analysis), we used this
SNP as a covariate in logistic regression. This conditional analysis
then identified the next best associated SNP (which was used as
a third covariate along with the first associated SNP and the
ancestry covariate). We proceeded to identify as many associations
as were statistically significant (FDR % 0.05) and added each
successive SNP as a covariate. Heterogeneity of ORs was tested
for in the logistic-regression framework with best-guess genotypes
in R.25
Statistical Analysis: SNP and HLA Data
We analyzed the HLA data in a logistic-regression model in which
each allele was taken in turn and was coded as a biallelic marker
(0, 1, or 2 copies of the allele), and we used the same PC forer 2, 2012
ancestry as we did with the SNP data. We estimated the OR for
each study separately and then combined the results by using
the inverse-variance method.23
Multiple testing was accounted for within each study by
permutation (maxT) in PLINK; 100,000 permutations were taken.
We combined the permuted p values across studies by using the
sample-size method for meta-analysis.23 Alleles were taken
as significantly associated if they had a combined adjusted p <
0.01. The number of permutations limited the strength of associ-
ation to 105 within each study, but this only affected the most
associated alleles, which were significant after the meta-analysis.
This procedure therefore has a lower bound for the estimated
p value because PLINK limits the p value to a minimum of
[1 / nperms þ 1] to avoid a p value of zero, but this is adequate
for detecting an adjusted value of less than 0.01. This permutation
adjustment was made for HLA-DRB1 alone within the HLA-DRB1
analysis. We also adjusted across all HLA loci for multiple testing
when we included all the HLA data.
A stepwise model search with HLA alleles and SNPs was per-
formed in R with the use of dosage values. For imputed genotypes,
this is a function of genotype probabilities. We analyzed all studies
together by using a covariate for study and by assuming random
effects for the PC covariate; we did this to ensure a different effect
size for each study (because each PCA was performed separately).
The ORs were assumed to be equal for all studies, although we
relaxed this assumption to test for heterogeneity (likelihood-ratio
test of differing ORs against equal ORs). The Bayesian information
criterion (BIC) was used as the variable-selection criterion in the
stepwise regression.
We used forward and backward selection for the stepwise regres-
sion.When combining the HLA alleles and the SNPs, we began the
search from a variety of starting positions: the null model (no vari-
ables), the best models for each of the HLA genes (HLA-B, HLA-C,
HLA-DRB1, HLA-DQA1, and HLA-DQB1), each HLA class (class I
alleles and class II alleles), individually significant HLA alleles,
and the best overall HLA model. The aim of this search was to
find the best set of SNPs and/or HLA alleles that are independently
associated with SLE as judged by the lowest BIC. To avoid local
minimum, it is a good idea to begin the search from as many start-
ing positions as possible. Therefore, we also started the search from
models similar to those that each stepwise search converged to by
substituting markers with alternatives in high LD. One must also
take care not to overfit by including multiple correlated explana-
tory variables, and so each model must be checked carefully; the
observed correlation among variables should be checked, and
the direction of effect for a particular explanatory variable should
not change between when it is analyzed on its own and when it is
conditional on other markers in the model. In our analysis, we
included SNPs that were independent of HLA alleles and also
SNPs that were correlated (SNPs that we identified as significant
in SNP-only analysis); therefore, we also conducted the model
search by including only HLA alleles and SNPs independent of
HLA alleles.
We did not use SNPTEST for this stepwise search because
SNPTEST does not perform stepwise regression. Using SNPTEST
in the first stage was for the purpose of gaining the best set of
SNPs given the imputation uncertainty. We did check that the
results for the SNPs returned from SNPTEST analyses did not
change (level of significance and p values) when we used the
pooled approach.
We used PLINK to perform conditional haplotype analysis of all
the studies’ data together by using a covariate for study and byThe Americanassuming random effects for the PC covariate; we did this to
ensure a different effect size for each study (because each PCA
was performed separately). We ran the analysis separately for
each of the alleles and SNPs (HLA-DRB1*03:01, HLA-DRB1*
15:01, HLA-DQA1*01:02, rs8192591, rs2246618, and rs2524117)
conditional on haplotypes formed by the alleles on each of
the extended HLA-DRB1*0301 and extended HLA-DRB1*15:01
haplotypes defined above.Results
Association: SNPs
After we applied quality-control procedures and SNP
imputation, the data contained 7,119 markers for 3,701
cases and 12,110 controls (see Table 1 for numbers of indi-
viduals per study and methods for full quality-control
information). We first analyzed the SNPs as single markers
by using logistic regression with a covariate to account for
intra-European ancestry (see Material and Methods). This
is step E-i in Figure 1. We used SNPTEST24 to account for
imputation uncertainty, and we combined the results
across studies by using the standard inverse-variance
method.23 Figure 2 displays a plot of the p values (log10
scale) for the meta-analysis, as well as plots for each
contributing study. These plots demonstrate the con-
sistency across studies and the relative contributions of
each data source. The most significant SNP from this anal-
ysis was used as the first covariate in the stepwise logistic
regression, again with SNPTEST, and results across studies
were combined with the inverse-variance method.
By setting the FDR at % 0.05, we identified five
SNPs with study-wide significance by using stepwise
multiple logistic regression. The top SNP (rs1150753
[32,167,845 bp]; meta p value ¼ 1.0 3 1071) in the
single-marker analysis was in a class III, intronic region
of TNXB (MIM 600985) and had an estimated OR of 2.20
(95% confidence interval [CI] ¼ 2.01–2.39). After we
conditioned on this SNP, the next most significant marker
(rs9271731 [32,701,590 bp]; meta p value ¼ 1.3 3 1029)
was in the intergenic class II HLA-DRB1–HLA-DQA1 region
and had an estimated OR of 1.58 (95% CI ¼ 1.46–1.71).
Further conditional analyses, using the two SNPs previ-
ously declared as associated as covariates, resulted in
three additional associated SNPs: rs9378200 (class III;
31,680,906 bp; intergenic NCR3 [MIM 611550]–AIF1
[MIM 601833] region; p ¼ 8.5 3 1011; OR ¼ 0.65 [95%
CI ¼ 0.57–0.74]), rs9469220 (class II; 32,766,288 bp;
upstream of HLA-DQB1; p ¼ 1.8 3 107; OR ¼ 0.83 [95%
CI ¼ 0.78–0.89]), and rs9265604 (class I; 31,407,429 bp;
intergenic HLA-B–HLA-C region; p ¼ 1.0 3 106; OR ¼
0.83 [95% CI ¼ 0.78–0.89]). The conditional p values
above are unadjusted for multiple testing; however, they
all passed a simple Bonferroni correction, which is highly
conservative given the LD in this region.
Table 2 contains marginal and multivariate ORs and p
values obtained from SNPTEST and PLINK on the five
SNPs that obtained study-wide conditional significance.Journal of Human Genetics 91, 778–793, November 2, 2012 783
Figure 2. Association Results
(A) Meta-analysis results.
(B) Individual study data.
Black points indicate raw data, and red points indicate imputed
data. Details on individual studies can be seen in Table 1, where
sample sizes are the following: 1,137 cases and 6,529 controls
for Illumina 550K, 413 cases and 1,927 controls for Illumina
317K, 210 cases and 1,707 controls for Affy500K, 1,012 cases
and 613 controls for the Illumina MHC Panel, 686 cases and 776
controls for Illumina Custom, and 338 cases and 621 controls
for Affy100K. In all plots, ‘‘E’’ is the lower bound for extended
class I, ‘‘1’’ is the lower bound for class I, ‘‘3’’ is the lower bound
for class III, ‘‘2’’ is the lower bound for class II, and ‘‘X’’ is the lower
bound for extended class II. Circled SNPs show in which class the
most associated SNP lies.A further step in this conditional analysis, using the five
associated SNPs as covariates, did not result in any addi-
tional markers that passed Bonferroni or FDR multiple-
testing procedures. The estimated ORs per study can be
seen in Table S9.
Association: HLA-DRB1 Alleles
Given the evidence of association between HLA-DRB1 and
SLE, we sought to deduce the relationship between the
associated SNPs and HLA-DRB1 alleles and to determine
whether there were association signals independent of
HLA-DRB1. To achieve this, we had to first impute HLA-
DRB1 in all studies (step C in Figure 1) and then determine
the HLA-DRB1 alleles to condition on in a repeat analysis
of the SNP data (step D in Figure 1). Table S10 con-
tains details of HLA-DRB1 imputation performance. In784 The American Journal of Human Genetics 91, 778–793, Novembsummary, the performance was comparable to that of
a recent study of the MHC in rheumatoid arthritis21 and
to that noted by the authors of HLA*IMP.20
Consistent with the analysis for the SNP data, we applied
logistic-regression models for each HLA-DRB1 allele and
used a covariate to account for intra-European ancestry.
This is step D-i in Figure 1. The meta-analysis of HLA-
DRB1 alleles confirmed previously declared associations
for HLA-DRB1*03:01 (OR ¼ 1.87 [95% CI ¼ 1.73–2.02];
p ¼ 1.17 3 1058) and HLA-DRB1*15:01 (OR ¼ 1.33
[95% CI ¼ 1.23–1.44]; p ¼ 1.92 3 1012). Table S11 con-
tains association results (OR, p value, and adjusted p value)
for all alleles.
We performed stepwise regression on HLA-DRB1 alleles
(see Material and Methods; step D-ii in Figure 1) again by
using a covariate to account for intra-European ancestry.
The bestHLA-DRB1model returned by this stepwise search
was DRB1*03:01 þ DRB*15:01 þ DRB1*08:01 þ DRB1*
13:02 þ DRB1*16:01. Conditional on these alleles as cova-
riates in a multivariate logistic-regression model, the only
allele showing marginal significance was HLA-DRB1*
14:01 (p ¼ 4.4 3 103).
Association: SNPs Conditional on HLA-DRB1
To determine whether there were association signals inde-
pendent of HLA-DRB1, we re-ran the association analysis
on SNPs as before but with the addition of a range of
HLA-DRB1 alleles as covariates (step E-ii in Figure 1). Alleles
were chosen as a result of an analysis ofHLA-DRB1 for asso-
ciation and prior knowledge of associated alleles. Because
HLA-DRB1*03:01 and HLA-DRB1*15:01 were the strongest
independent signals and were reported in many studies
previously, they were chosen first as covariates. We also
used the alleles specified in the best HLA-DRB1 model,
identified above, as covariates.
The results were consistent regardless of which HLA-
DRB1 alleles were chosen as covariates. Using DRB1*
03:01 þ DRB1*15:01, we found evidence of associa-
tion with rs2246618 (class I; MICB [MIM 602436]),
rs8192591 (class III; NOTCH4 [MIM 164951]), and
rs12529318 (class II; HLA-DRA–HLA-DRB5) (FDR %
0.05). Repeating the analysis with the use of DRB1*
03:01 þ DRB1*15:01 þ DRB1*08:01 þ DRB1*13:02 þ
DRB1*16:01 as covariates also resulted in association
with rs2246618 and rs8192591; however, rs12529318
was replaced by rs2524117 (class I; downstream of
HLA-C). The class II SNP (rs12529318) perhaps tagged
an effect (or effects) at classical loci (this effect was picked
up with the extended set of DRB1 alleles); there was
strong LD (R2 ¼ 0.9; D0 ¼ 0.96) between rs12529318
and HLA-DRB1*08:01.
The effect sizes for the two SNPs (rs2246618 and
rs8192591) that were consistently associated when they
were conditional on HLA-DRB1 were also consistent
between analyses; see Table S12 for ORs and p values for
all four SNPs showing significance when conditional on
either set of HLA-DRB1 alleles.er 2, 2012
Table 2. Association Results from Logistic Regression
SNP (A1, A2)
Marginal Multivariate Model
LocationOR (95% CI) p Values OR (95% CI) p Values
rs1150753 (G, A) 2.20 (2.01–2.39) 1.0 3 1071 1.67 (1.52–1.84) 1.6 3 1026 class III, intronic TNXB
rs9271731 (A, G) 1.34 (1.25–1.45) 2.5 3 1014 1.40 (1.29–1.51) 3.2 3 1017 class II, intergenic HLA-DRB1–HLA-DQA1
rs9378200 (C, T) 0.59 (0.52–0.67) 8.2 3 1017 0.64 (0.56–0.74) 1.7 3 109 class III, upstream of BAT2
rs9469220 (T, C) 0.65 (0.61–0.68) 1.1 3 1047 0.85 (0.79–0.91) 1.0 3 106 class II, downstream of HLA-DQA1
rs9265604 (G, A) 0.83 (0.78–0.89) 1.3 3 108 0.88 (0.82–0.93) 7.6 3 105 class I, downstream of HLA-B
Estimated ORs (95% CIs), p values, and Bonferroni-adjusted p values are shown. ‘‘Marginal’’ displays the single-marker association results from SNPTEST
(averaging over genotype uncertainty). ‘‘Multivariate Model’’ contains results when all five SNPs in the logistic regression were included, when the genotypes
with maximum probability were taken, and when the model was fit with PLINK. The p values for the multivariate model tended to be less significant (than
the single-marker p values) because extra degrees of freedom were taken up by the inclusion of five markers in the regression. In the first column, the first of
the two alleles is the minor allele associated with the effect, and the risk allele is in bold (for example, G is the risk allele for rs1150753, whereas C is the protective
allele for rs9378200). The following abbreviations are used: A1, allele 1; A2, allele 2; OR, odds ratio; and CI, confidence interval.HLA Associations: HLA-B, HLA-C, HLA-DQA1, and
HLA-DQB1
We found evidence of SNPs associated with SLE indepen-
dently of HLA-DRB1 alleles. However, our broader aim
was to ask whether the association signals within the
MHC could be explained completely by HLA alleles. To
achieve this, we had to impute HLA class I and class II
alleles (step C in Figure 1). The accuracy of imputation
for HLA-B and HLA-DQB1 was very similar to a study of
the MHC in rheumatoid arthritis21 (HLA-DQA1 was not
included in the RA study), and the comparison is discussed
in the Material and Methods (further details are provided
in the Supplemental Data.
Consistent with the analysis for the SNP data, we applied
logistic-regression models to each of the class I and class II
alleles and used a covariate to account for intra-European
ancestry (step D-i in Figure 1).
The meta-analysis of class I alleles found very strong
evidence of association for HLA-B*08:01 (OR ¼ 1.84
[95% CI ¼ 1.70–1.99]; p ¼ 3.58 3 1053) and HLA-C*
07:01 (OR ¼ 1.57 [95% CI ¼ 1.47–1.69]; p ¼ 6.26 3
1036). The other alleles were not significant at the 0.05
level after multiple-testing adjustment (see Material and
Methods). Table S11 contains association results for all
alleles.
Given the known strong LD within class II, it is not
surprising that we found many association signals at
HLA-DQA1 and HLA-DQB1. In order to address this corre-
lation, we also performed analyses of HLA-DQ alleles
conditional on the HLA-DRB1 alleles DRB1*03:01 and
HLA-DRB1*15:01. From this analysis, we found evidence
of association independent of DRB1*03:01 and HLA-
DRB1*15:01 (after adjusting for multiple testing) at
HLA-DQA1*05:01, HLA-DQA1*01:01, HLA-DQA1*01:02,
HLA-DQB1*03:01, and HLA-DQB1*03:03 (p ¼ 6.66 3
1015, p ¼ 8.88 3 1015, p ¼ 9.77 3 1015, p ¼ 4.61 3
1022, and p ¼ 1.50 3 1010, respectively). Further
details can be seen in the Supplemental Data and
Table S11.The AmericanModel Choice: SNPs þ HLA-B, HLA-C, HLA-DQA1,
HLA-DQB1, and HLA-DRB1
We identified SNPs independently associated with SLE and
also HLA associations. A summary of these findings can be
seen in Table 3. However, we aimed to answer the more
refined question as to whether the association within the
MHC resides with HLA alleles only, SNPs only, or a combi-
nation of both HLA alleles and SNPs. To answer this, we
searched for the best combination of SNPs and/or HLA
alleles that independently explained SLE as an outcome.
This is the final step (F) in Figure 1. Our model-selection
criterion was the BIC because this has a heavy penalty
for the inclusion of variables. However, we found that
the results did not differ from those obtained with the
AIC (Akaike information criterion), a model-choice metric
that uses a weaker penalty (when sample sizes are large)
than does the BIC for the inclusion of variables.
We ran a stepwise logistic regression by using all HLA
alleles (class I and II) together with the five SNPs identified
as independently associated without reference to the HLA
alleles (Table 2) and the SNPs (rs2246618, rs8192591,
rs2524117, and rs12529318) identified by the regression
conditional on HLA-DRB1 alleles. The model search began
from various starting points (seeMaterial andMethods and
Table S13), including the simplest model with no HLA
alleles or SNPs and single-marker models with HLA alleles
or SNPs that were significant in a single-marker associa-
tion. We also used the best HLA model, as well as the
best models from individual HLA loci, as a starting point
(see Material and Methods; step D-ii in Figure 1). In all
models, we included the same covariate to account for
intra-European ancestry as in all previous analyses (of
HLA alleles and SNPs).
Table 4 displays the model (model C) that resulted as the
best fit to the data from this search. Several other models
are displayed as they were within a BIC of 10 of the model
with the lowest BIC. There is some uncertainty as to
the best model. However, the following six variables
(model F) were consistently included in models withinJournal of Human Genetics 91, 778–793, November 2, 2012 785
Table 3. Summary of SNPs and HLA Alleles Reported as Associated within Each Analysis
Analysis Marker Gene Class
Analysis of SNPsa
Candidate SNPs independently associated from SNP-only analysis rs1150753 intronic region of TNXB III
rs9271731 HLA-DRB1–HLA-DQA1 II
rs9378200 NCR3-AIF1 III
rs9469220 upstream of HLA-DQB1 II
rs9265604 HLA-B–HLA-C I
HLA-DRB1 Analysisb
Candidate alleles independently associated from class II HLA-DRB1 analysis HLA-DRB1*03:01 HLA-DRB1 II
HLA-DRB1*15:01 HLA-DRB1 II
HLA-DRB1*08:01 HLA-DRB1 II
HLA-DRB1*13:02 HLA-DRB1 II
HLA-DRB1*16:01 HLA-DRB1 II
HLA-DRB1*14:01 HLA-DRB1 II
Analysis of SNPs Conditional on HLA-DRB1c
Candidate SNPs from analysis conditional on HLA-DRB1 alleles rs2246618 MICB I
rs2524117 downstream of HLA-C I
rs8192591 NOTCH4 III
rs12529318 HLA-DRA–HLA-DRB5 II
Analysis of HLA Class Id
Candidate alleles from class I analysis HLA-B*08:01 HLA-B I
HLA-C*07:01 HLA-C I
Analysis of HLA-DQA1 and HLA-DQB1 Conditional on HLA-DRB1e
Candidate alleles from class II HLA-DQA1 and HLA-DQB1 analysis conditional
on DRB1
HLA-DQA1*05:01 HLA-DQA1 II
HLA-DQA1*01:01 HLA-DQA1 II
HLA-DQA1*01:02 HLA-DQA1 II
HLA-DQB1*03:01 HLA-DQB1 II
HLA-DQB1*03:03 HLA-DQB1 II
aAnalysis of SNPs only.
bAnalysis of HLA-DRB.
cAnalysis of SNPs conditional on HLA-DRB1.
dAnalysis of HLA class I only (these two signals are not independent [R2 ¼ 0.71; D0 ¼ 0.98]).
eHLA-DQA1 and HLA-DQB1 alleles associated when conditioned on HLA-DRB1. These signals, which were the only alleles significant in single-marker association
tests conditional on DRB1, are not necessarily independent. The bolded SNPs and alleles are those included in the best model for independent association.a BIC of 10 of the best model: HLA-DRB1*03:01 þ HLA-
DRB1*08:01 þ HLA-DQA1*01:02 þ rs2246618 (MICB) þ
rs8192591 (NOTCH4) þ rs2524117 (HLA-C). The uncer-
tainty relates to whether we find evidence of a further
two signals at HLA-DRB1*14:01 and HLA- DQB1*03:01
(model C) or a single further signal at HLA-DQB1*03:02
(model D). However, HLA-DQB1*03:02 does not seem to
be an independent effect because the marginal effect was
observed to be slightly protective and nonsignificant
(OR ¼ 0.95 [95% CI ¼ 0.87–1.05]; p ¼ 0.31), whereas the
effect is risk in model D (p ¼ 1 3 104). Table 5 contains
OR estimates and p values for all variables in Table 4models
CandF. The estimatedORsper study canbe seen inTable S4.786 The American Journal of Human Genetics 91, 778–793, NovembThe possible effect of HLA-B*08:01 is interesting.
Marginally, this is very significant (OR ¼ 1.84 [95% CI ¼
1.70–1.99]; p¼ 3.583 1053), whereas inmodel E (Table 4),
where HLA-B*08:01 replaces one of the class I SNPs
(rs2246618), its effect is modest (OR ¼ 1.19 [95% CI ¼
1.05–1.33]; p ¼ 0.008). This allele is clearly not indepen-
dent of rs2246618, which is in class I (MICB; R2 ¼ 0.29;
D0 ¼ 0.93); however, rs2246618 is a better explanation of
the data than is the combination of HLA-B*08:01 and
HLA-DQB1*03:02 (model F versus model E).
The model including only the five SNPs in Table 2 is
strongly rejected with these data; the BIC gives a Bayes-
factor (BF) estimate of 90 in favor of the model with HLAer 2, 2012
Table 4. HLA Alleles and SNPs Contained in Models within a BIC of 10 of the Model with the Lowest BIC and Lowest AIC
Model Model Description Variables in Model
Difference
in BIC
Difference
in AIC
Bayes
Factora
Markers
Considered Start
A best set of SNPs
independently
associated with SLE
rs1150753 þ rs9271731 þ rs9378200 þ
rs9469220 þ rs9265604
þ9 þ32 90.02 all 7,122 SNPs null
B best set of HLA
(class I and II) alleles
associated with SLE
HLA-DRB1*03:01 þ HLA-
DRB1*08:01 þ HLA-DQA1*01:02 þ
HLA-DRB1*01:02 þ HLA-DRB1*14:01 þ
HLA-B*08:01 þ HLA-DQB1*03:01 þ
HLA-DQB1*03:03 þ HLA-C*12:03
þ25 þ18 27K all HLA Alleles null, multiple
HLA modelsb
C model with lowest
BIC
HLA-DRB1*03:01 þ HLA-
DRB1*08:01 þ HLA-DQA1*01:02 þ
HLA-DRB1*14:01 þ HLA-DQB1*03:01 þ
rs2246618 þ rs8192591 þ
rs2524117
0 0 1.00 all HLA alleles
(except DRB1*03:02)
plus SNPs
independent of
HLA-DRB1
null, multiple
HLA modelsb
D alternative model HLA-DRB1*03:01 þ HLA-
DRB1*08:01 þ HLA-DQA1*01:02 þ
HLA-DQB1*03:02 þ rs2246618 þ
rs8192591 þ rs2524117
þ1 þ9 1.65 all HLA alleles plus
SNPs independent
of HLA-DRB1
null, multiple
HLA modelsb
E alternative model HLA-DRB1*0301 þ HLA-
DRB1*0801 þ HLA-DQA1*0102 þ
HLA-B*08:01 þ HLA-DQB1*0302 þ
rs8192591 þ rs2524117
þ7 þ15 33.12 all HLA alleles plus
SNPs independent
of HLA-DRB1
null, multiple
HLA modelsb
F set of HLA alleles and
SNPs consistently
observed in
models above
HLA-DRB1*03:01 þ HLA-
DRB1*08:01 þ HLA-DQA1*01:02 þ
rs2246618 þ rs8192591 þ
rs2524117
þ6 þ22 20.09 N/A N/A
We also include the best HLAmodel (model B) and themodel (using only SNPs) returned by stepwise logistic regression (model A). The following abbreviations are
used: BIC, Bayesian information criterion; AIC, Akaike information criterion; SLE, systemic lupus erythematosus; and HLA, human leukocyte antigen.
aThe estimate of the Bayes factor is taken from the BIC as an estimate of the log of the marginal likelihood under the assumption of vague priors for the ORs; for
example, the estimate of the Bayes factor for model C to model A is Exp(0.53 [BICA – BICC]). The alleles and SNPs that are consistently included across models are
in bold. ‘‘Null’’ refers to no markers included. The column ‘‘Start’’ describes models taken as starting models in the stepwise regression.
bSearch started from multiple points, namely individually associated HLA alleles and best set of alleles for each class: class I (HLA-B*08:01 þ HLA-B*57:01 þ HLA-B*
44:02 þ HLA-C*12:03), class II (HLA-DRB1*03:01 þ HLA-DQA1*01:02 þ HLA-DRB1*08:01 þ HLA-DQB1*03:02 þ HLA-DQB1*03:03), HLA-B (HLA-B*08:01 þ HLA-B*
57:01 þ HLA-B*44:02), HLA-C (HLA-C*07:01 þ HLA-C*12:03 þ HLA-C*03:04 þ HLA-C*07:02), HLA-DRB1 (HLA-DRB1*03:01 þ HLA-DRB1*15:01 þ HLA-DRB1*
08:01 þ HLA-DRB1*13:02 þ HLA-DRB1*16:01), HLA-DQA1 (HLA-DQA1*01:02 þ HLA-DQA1*05:01 þ HLA_DQA1*04:01), and HLA-DQB1 (HLA-DQB1*02:01 þ
HLA-DQB1*06:02þ HLA-DQB1*03:01þ HLA-DQB1*03:03þ HLA-DQB1*05:03 þ HLA-DQB1*05:01). We found model B by starting from the null with no variables.
We foundmodel D by starting from the null model with no variables. We foundmodel C by removing HLA-DQB1*03:02 from the search (because there is evidence
that this is not an independent signal; see Results). We found model E directly by starting the search with HLA-B*08:01 alone. Note that we found models C–E by
only including SNPs independent of the HLA alleles; we found no models within a BIC of 10 of the minimum when we included the additional five SNPs.plus SNPs (see Table 4). Furthermore, the model including
only HLA alleles is very strongly rejected with these data;
the BIC gives a BF estimate of over 1,000 in favor of the
model with HLA plus SNPs. Our data therefore strongly
favor a combination of HLA alleles and SNPs as opposed
to a model with only HLA alleles or only SNPs. The posi-
tions of each marker within the MHC can be seen in
Figure 3, and forest plots for the log ORs (marginally for
each marker) can be seen in Figure 4.
Confounding Effects Created by LD among SNPs and
HLA Alleles
Weobservedmany SNPs andHLA alleles whose effectswere
significant marginally but that could be explained by LD
with other alleles. Our study cannot claim to identify all
of these confounding effects, but we can explain some.
See Figures S2A (numbers indicate R2) and S2B (numbers
indicate D0) for the LD structure in our data among all
HLA alleles and all SNPs considered in our results.
An important example in this study is the associations
observed in the analysis of SNP-only data. These sameThe Americanfive SNPs were also observed to be the only significant asso-
ciations when we included HLA-DRB1 alleles (along with
the eight candidate SNPs) and ran a conditional logistic
regression starting from no variables. The reason for this
is that the most associated marker (rs1150753) was cor-
related with HLA-DRB1*03:01 (R2 ¼ 0.73; D0 ¼ 0.92).
Therefore, when we conditioned on this SNP, the effect
at HLA-DRB1*03:01 was not observed to be very strong
(p ¼ 0.006), whereas we found that the class II SNP
rs9271731 was very significantly associated; this latter
SNP tagged HLA-DRB1*15:01 (R2 ¼ 0.68; D0 ¼ 0.99). The
most associated marker, rs1150753, was also correlated
with class I alleles, such as HLA-B*08:01 (R2 ¼ 0.72; D0 ¼
0.89), and so this HLA allele was also not significant
when it was conditioned on rs1150753. The starting point
for conditional logistic regression (stepwise regression)
therefore affects all subsequent association signals.
Related specifically to the HLA, another important
example in our data is HLA-DRB1*15:01, which was
marginally significant (OR ¼ 1.33 [95% CI ¼ 1.23–1.44];
p ¼ 1.92 3 1012), but not when the effect ofJournal of Human Genetics 91, 778–793, November 2, 2012 787
Table 5. Effect Sizes and p Values for Variables in Models C and F in Table 4
Variable
Model C Model F Marginal
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
DRB1*03:01 1.67 (1.51–1.84) 4.3 3 1027 1.77 (1.60–1.95) 2.1 3 1036 1.87 (1.73–2.02) 1.17 3 1058
DRB1*08:01 1.57 (1.29–1.91) 2.8 3 106 1.67 (1.40–1.99) 7.7 3 108 1.34 (1.12–1.60) 1.32 3 103
DQA1*01:02 1.46 (1.35–1.58) 3.4 3 1022 1.55 (1.44–1.68) 1.4 3 1032 1.31 (1.22–1.40) 9.77 3 1015
DRB1*14:01 0.65 (0.51–0.82) 2.2 3 104 N/A N/A 0.56 (0.45–0.70) 2.58 3 107
DQB1*03:01 0.84 (0.78–0.91) 1.7 3 104 N/A N/A 0.68 (0.63–0.73) 4.61 3 1022
rs2246618 (A, G) 1.17 (1.09–1.27) 9.6 3 106 1.16 (1.07–1.26) 2.3 3 105 1.49 (1.40–1.58) 1.76 3 1036
rs8192591 (A, G) 0.53 (0.65–0.44) 1.7 3 109 0.56 (0.46–0.68) 1.7 3 108 0.54 (0.46–0.63) 1.33 3 1013
rs2524117 (G, A) 1.17 (1.09–1.26) 8.8 3 106 1.19 (1.10–1.28) 3.0 3 106 1.34 (1.26–1.43) 8.20 3 1021
The last column has the marginal effect sizes and p values. For the SNPs, the first allele is the minor allele associated with the effect, and the risk allele is in bold. The
following abbreviations are used: OR, odds ratio; CI, confidence interval, and N/A, not available.HLA-DQA1*01:02was accounted for (p¼ 0.162). However,
when we conditioned on HLA-DRB1*15:01, the effect of
HLA-DQA1*01:02 was still borderline significant (OR ¼
1.23 [95% CI ¼ 1.10–1.38]; p ¼ 2.78 3 104). This suggests
that the observed association of HLA-DRB1*15:01 is due to
its correlation with HLA-DQA1*01:02, whereas the associ-
ation of HLA-DQA1*01:02 cannot be explained by its
correlation with HLA-DRB1*15:01.
HLA-DQA1*01:02 was also in LD (R2 ¼ 0.16; D0 ¼ 0.96)
with HLA-DRB1*13:02, which suggests that our signal at
HLA-DQA1 could be a composite of two DRB1 signals.
However, we did not find evidence of this in our data; re-
placing DQA1*01:02 with DRB1*15:01 þ DRB1*13:02
gave a BIC difference of 14 in favor of DQA1*01:02.
HLA-DQA1*01:02 lies on various HLA-DRB1–HLA-DQB1
haplotype backgrounds,26 including HLA-DRB1*16:01, so
we also considered the HLA-DQA1*01:02 effect against
these haplotypes. If the HLA-DQA1*01:02 is the causal
locus, then there should be no heterogeneity in risk over
these haplotypes; however, if there is heterogeneity in
risk, then HLA-DRB1 might be the likely source of risk.
We found no evidence of heterogeneity of risk (p ¼ 0.6).
See Table S14 for more details on haplotypes and analysis.RNA Expression Analysis
We sought to determine whether any of the SNPs indepen-
dently associated with SLE show evidence of correlation
with cis-acting gene expression. From the Gene Expression
Omnibus repository (which contains RNA extracted from
lymphoblastoid cell lines in unrelated HapMap individ-
uals; see Material and Methods), we found modest
evidence that the class I SNP rs2246618 is correlated
with HLA-C expression (p ¼ 0.007; risk allele associated
with reduced expression). We found no evidence
that rs8192591 is correlated with expression of NOTCH4
(p ¼ 0.65) and no evidence that rs2524117 is associated
with expression of HLA-C (p ¼ 0.97). We conducted six
tests in total (see Material and Methods), and so
rs2246618 is significant at the 0.05 level.788 The American Journal of Human Genetics 91, 778–793, NovembHaplotype Analysis
The results we have presented include HLA alleles and
SNPs that show statistical evidence of independent associ-
ation with SLE. However, this might not translate directly
to independent loci as a result of the extended LD known
to exist in the MHC; it is very possible that markers that
seem to be acting independently with respect to genotype
risk could be on a shared haplotype. We therefore used
PLINK15 to test each of the HLA alleles and SNPs for asso-
ciation independent of the HLA-DRB1*03:01 and HLA-
DRB1*15:01 haplotype backgrounds (see Material and
Methods).
The results of the conditional haplotype analysis can be
seen in Table 6. We confirmed that rs2246618 and
rs8192591 are associated with SLE independently of the
extended HLA-DRB1*03:01 haplotype and the HLA-
DRB1*15:01 haplotype. We found that rs2524117 might
tag the HLA-DRB1*03:01 haplotype because we failed to
find evidence of a risk effect for this SNP when it was
conditioned on the background for the alleles contained
in this haplotype. However, we did find evidence of an
independent risk effect for HLA-DRB1*03:01 (p ¼ 0.002,
Bonferroni adjusted < 0.05). We also found evidence that
HLA-DQA1*01:02 has a risk effect independent of the
extended HLA-DRB1*15:01 haplotype (p ¼ 0.003).
These analyses do not implicate HLA-DRB1*15:01
because this allele’s observed effect is not independent
of the extended haplotype (p ¼ 0.251). Although the
class I SNP rs2246618 has an effect independent of the
HLA-DRB1*03:01 haplotype, neither HLA-B*08:01 nor
rs2524117 were found to have effects independent of
the haplotype. These two variables (HLA-B*08:01 and
rs2524117) most likely tag the same effect, and rs2524117
is the more likely candidate on the basis of our analysis.Discussion
We have performed the largest study to date of the MHC in
SLE by bringing together six data sets from previouslyer 2, 2012
Figure 3. Representation of Three SNPs Associated Independently of Classical HLA Alleles and the Three HLA Alleles that
Consistently Appear in the Best Models Explaining SLE Risk
The bottom left panel shows LD as measured by D0, and the bottom right panel shows LD as measured by r2.published studies in ameta-analysis. Previous to this study,
many association signals had been found in the MHC;
however, very little was understood about which alleles
were the driving force behind the association and which
were associated as a result of correlation (LD). The class II
alleles HLA-DRB1*03:01 and HLA-DRB1*15:01 have been
consistently reported as being associated with SLE. Other
class II loci (HLA-DQA1 and HLA-DQB1) have also been
reported as being associated; however, they are in strong
LD with HLA-DRB1, and so the observed association could
simply be HLA-DRB1 tagging effects. This is also true of
observed associations at SNPs across the MHC.
Our results support and refine previous findings (a UK
study,5 a US study,7 and the Illumina Custom6) of multiple
signals in the MHC for a population of European ancestry.The AmericanThe UK study5 reported two independent signals: one in
class III (rs419788 [32,036,778 bp]) and one in class II
(HLA-DRB1*03:01). This class III marker is significant in
our meta-analysis (p ¼ 1.4 3 1047). However, it is not
significant (p ¼ 0.33) when it is conditioned on both the
most associated single marker, rs1150753, and the second
independent signal (rs9271731; class II), which suggests
that this SNP tags class II and III signals. The UK study
did not find evidence that a class I SNP (rs2523589
[31,435,313 bp]), which was associated as a single marker,
was independent ofHLA-DRB1*03:01. We found an associ-
ation at this marker (p ¼ 1.5 3 1021), but this was not
independent of our most associated marker (p ¼ 1.5 3
104). This suggests that the class I marker reported in
the UK study in fact tags class II and III effects and thatJournal of Human Genetics 91, 778–793, November 2, 2012 789
Figure 4. Forest Plots of the Log ORs for the HLA Alleles and SNPs in the Final Model for SLE Association within the MHC
The error lines cover 95% confidence intervals. The box sizes are relative to study size. Study reference codes are the following: 1, Illumina
550K; 2, Illumina 317K; 3, Affy500K; 4, Illumina MHC Panel; 5, Illumina Custom; and 6, Affy100K.the class I signal lies elsewhere. The class I marker reported
in the UK study is not correlated (R2¼ 0.007) with the SNP,
rs2246618 (class I; 31,586,965 bp), that we found to be
associated independently of HLA-DRB1. The US study7
also found class I association signals independent of
HLA-DRB1*03:01.
The Illumina Custom study found that the strongest
association was in class III (rs1269852 [32,151,660 bp])
and that this SNP was still significant when it was condi-
tioned on HLA-DRB1*03:01, whereas the HLA-DRB1*
03:01 effect was not significant when it was conditioned
on rs1269852. They hypothesized that their imperfect
HLA imputation might have underestimated the HLA-
DRB1*03:01 effect. rs1269852 is significantly associated
in our meta-analysis (p ¼ 1.2 3 1071) and is very corre-
lated with our most significant single marker, rs1150753
(R2 ¼ 0.99). We also found that the significance of HLA-790 The American Journal of Human Genetics 91, 778–793, NovembDRB1*0301 decreased (p ¼ 0.0006) when we conditioned
on the most strongly associated marker (rs1150753).
However, when we conditioned on the class III SNP
rs8192591 (the class III SNP in our final model), HLA-
DRB1*0301 was significant (p ¼ 5.8 3 1058). In fact,
when we conditioned on all markers in our final model
(see Table 5), HLA-DRB1*03:01 was still very significant.
Our results suggest that the most associated class III SNP
tags both HLA-DRB1*03:01 and an association in class I
(which is why it was significant when it was conditioned
on HLA-DRB1*0301) and that including this marker in
a model of SLE association might confound subsequent
conditional associations. All these previous studies con-
tributed samples to this meta-analysis, so the consistencies
are expected. However, the size of our data set allowed us to
identify more independent signals and disentangle HLA
from non-HLA associations.er 2, 2012
Table 6. p Values for Conditional Haplotype Results
Location of
Gene or SNP
HLA Allele
or SNP
Haplotype Conditioned on
Hap-DRB1*03:01 Hap-DRB1*15:01
Class II DRB1*03:01 0.002* N/A
Class II DRB1*15:01 N/A 0.251
Class II DQA1*01:02 1.19 3 1021*** 0.00264*
Class III:
upstream
of NOTCH4
rs8192591 9.61 3 105** 0.000346**
Class I:
downstream
of HLA-C
rs2524117 0.921 5.22 3 1014***
Class I: MICB rs2246618 0.000919* 2.21 3 1023***
Each allele or SNP in the first column was tested for association with SLE and
was conditional on the haplotypes formed by the alleles in each of the haplo-
types: Hap-DRB1*03:01 (HLA-B*08:01 – HLA-C*07:01 – DRB1*03:01 – DQA1*
05:01 – DQB1*02:01) and Hap-DRB1*15:01 (HLA-B*07:02 – HLA-C*07:02 –
DRB1*15:01 – DQA1*01:02 – DQB1*06:02). The null hypothesis is that there
is no association for the allele or SNP when the background haplotype is fixed.
We failed to reject this, for example, for HLA-DRB1*15:01when we conditioned
on Hap-DRB1*15:01, whereas we did reject this for HLA-DQA1*01:02when we
conditioned on Hap-DRB1*15:01 at the adjusted 0.05 level. The p values in the
table are not corrected for multiple testing; assuming ten independent tests
and taking a Bonferroni correction leads to those rejected at the 0.05 level
(*), those rejected at the 0.01 level (**), and those rejected at the 0.001 level
(***). The following abbreviations are used: HLA, human leukocyte antigen;
and N/A, not available.Approaches such as stepwise regression can be mis-
leading because they are dependent on the primary associ-
ation; the first signal might tag two or more associated
loci, which will then be missed in further conditional
analyses. This is evident from our data (analysis with
SNPs and all HLA-DRB1 alleles); stepwise regression, begin-
ning from a model with no variables, only returns the five
SNPs identified from the SNP-only analysis as significant
and misses HLA-DRB1*03:01. Our approach was to per-
form a multistart stepwise procedure in which we begin
each search from HLA alleles with evidence a priori to be
associated with disease and alleles identified as associated
with subanalyses of our current data. Importantly, our
analyses converged to just a few models, the best of which
was overwhelmingly a better fit (as judged by the BIC or
AIC) to the data than was a model with HLA alleles
alone or with SNPs alone. The approach we have taken
will be useful for analyzing other immune-related dis-
eases in which there are multiple association signals at
the MHC.
We identified the best model for genetic association by
considering classical HLA loci (HLA-B, HLA-C, HLA-DRB1,
HLA-DQA1, and HLADQB1) and 7,199 SNPs across the
extended MHC. From these data, there is strong evidence
that the alleles DRB1*03:01, DRB1*08:01 and DQA1*
01:02 are the driving force behind classical HLA associa-
tion signals. In class II, there are additional signals that
are likely to be HLA-DRB1*14:01 and HLA-DQB1*03:01,
but we cannot completely rule out HLA-DRB1:11 alleles,
such asHLA-DRB1*11:01, because these had lower imputa-The Americantion accuracy than did other common (MAF >1%) HLA-
DRB1 alleles. We found evidence that three SNPs
(rs2246618 [class I, MICB], rs8192591 [class III, upstream
of NOTCH4], and rs2524117 [class I, downstream of
HLA-C]) are associated independently of HLA alleles.
However, because we could not validate our imputation
of HLA-C alleles, we cannot rule out the possibility that
rs2246618 tags a poorly imputed HLA-C allele. Our results
also suggest that the often reported association at HLA-
DRB1*15:01 is due to this allele’s correlation with HLA-
DQA1*01:02 because we found that the data are better
explained by HLA-DQA1*01:02. Both of these alleles
were imputed, but HLA-DRB1*15:01 had slightly better
accuracy in our validation (Tables S10A, S10B, and S10D),
and so our finding cannot be explained by lower power
as a result of imputation uncertainty for HLA-DRB1*15:01.
On subsequent conditional haplotype testing, we found
that rs2524117 most likely tags the extended HLA-DRB1*
03:01 haplotype (HLA-A*01:01 – C*07:01 – B*08:01 –
DRB1*03:01 – DQA1*05:01 – DQB1*02:01). This result
does not reject the additional association in class I; rather,
it is a lack of evidence that the signal arises from
rs2424117. Therefore, although our best model for associ-
ation does include this SNP (the BIC without this marker is
worse by 12), we only report association independent of
classical HLA alleles at rs2246618 and rs8192591. The
other class I SNP (rs2246618), which we found to be corre-
lated with HLA-C expression, was associated indepen-
dently of both haplotypes, as was rs8192591. We also
tested each of the associated HLA alleles and SNPs for
dominant and recessive effects (see Table S15); with the
exception of rs2524117, which is most likely dominant,
none showed significant deviation from an additive
model.
In summary, we performed a large meta-analysis of SLE
studies of European ancestry to determine association at
classical HLA genes and SNPs independent of these loci.
Our results extend and refine the genetic contribution of
the MHC region to risk of SLE. There was some uncertainty
in our model choice, but the inclusion of the classical
HLA alleles HLA-DRB1*03:01, HLA-DRB1*08:01, and
HLA-DQA1*01:02 was clear. The class III SNP rs8192591
was associated independently of both the extended HLA-
DRB1*03:01 and HLA-DRB1*15:01 SLE risk haplotypes,
which implies either a further independent association at
HLA-DRB1 or HLA-DQ or an effect outside of classical
loci, possibly at NOTCH4. Furthermore, the class I SNP
rs2246618 was associated independently of both the
extended HLA-DRB1*03:01 and HLA-DRB1*15:01 SLE
risk haplotypes and was possibly correlated with HLA-C
expression. Our results are not determined by the most
associated signal in any locus within the MHC (SNPs or
HLA alleles) because our approach, using multiple stepwise
regression analyses, converged on just a few HLA alleles
and SNPs, which are displayed in Table 4. This study has
provided evidence that the genetic contribution to SLE
within the MHC is composed of several independentJournal of Human Genetics 91, 778–793, November 2, 2012 791
loci, some of which are most likely independent of
classical HLA alleles.Supplemental Data
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